Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
about
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsPhase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients.Platinum-based compounds for the treatment of metastatic breast cancer.Emerging drugs in metastatic breast cancer
P2860
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
@ast
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
@en
type
label
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
@ast
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
@en
prefLabel
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
@ast
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
@en
P2093
P1433
P1476
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
@en
P2093
Dolores Gallardo
Enrique Avila
Francisco Alexander
German Calderillo
Guillermo Aguirre
Homero Fuentes
Jorge Otero
Leonel Perez
Luis F Oñate-Ocaña
Marcelino Ramirez
P304
P356
10.1097/00001813-200606000-00011
P577
2006-06-01T00:00:00Z